A 53-year-old woman was initially evaluated for abdominal discomfort and found to have bulky bilobar hepatic neuroendocrine tumor with unidentified primary. Biopsy of a liver lesion revealed well-differentiated neuroendocrine tumor, WHO G1, Ki-67 2% with mitotic rate 1/mm2. Since her tumor progressed during initial treatment with octreotide depot injections, she was switched to capecitabine/temozolomide, but again slowly progressed. After discussion in a multidisciplinary neuroendocrine tumor board, the decision was made to proceed with surgical resection. Her preoperative imaging (Fig. 1) showed bilobar disease with dominant masses abutting the right and left hepatic pedicles as well as the right and middle hepatic veins with the left hepatic vein free of tumor.
WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.